Medical Spa and Aesthetics Marketing Report
Aesthetics is the most local business in regulated healthcare. Patients search for a provider near them, not a national brand, which makes the med-spa lane unusually open compared with telehealth-heavy verticals. This hub tracks that opening quarter by quarter and always shows the latest edition.
The risk in aesthetics rides on the regulated products behind the services. Botox, fillers, lasers, and weight-loss treatments each carry claim rules, and the letters follow the claims. The reports show where demand concentrates locally and how to compete for it without inheriting the warning-letter exposure that comes with overstated product marketing.
Latest edition · Q2 2026
Medical Spa / Aesthetics Marketing, Q2 2026: Enforcement, Search Demand, and AI Visibility
Read the Q2 2026 edition →Other reports
Healthcare Marketing and Compliance Report
The cross-vertical flagship. FDA and FTC enforcement trends alongside search demand and AI-assistant visibility across every regulated healthcare vertical we track.
GLP-1 and Weight Loss Marketing Report
The gold rush and the crackdown. Where GLP-1 and weight-loss demand is going, how enforcement is tightening, and which brands own the AI answers.
TRT and Hormone Marketing Report
Hormone optimization sits next to a grey market of SARMs and compounded products. Where demand is, where the enforcement edge is, and who wins AI answers.
Peptide Marketing Report
The sharpest enforcement edge in the field. Peptides live in an FDA grey zone of 503A and 503B compounding and research-use-only marketing.
Every edition is drawn from the Authoritize Atlas, our corpus of FDA and FTC actions, and from live search and AI-citation measurement. Screen your own marketing against the same rules with the free Claim Checker.